Skip to main content
. Author manuscript; available in PMC: 2019 Jan 18.
Published in final edited form as: ACS Appl Mater Interfaces. 2018 May 15;10(21):17792–17808. doi: 10.1021/acsami.8b05607

Figure 5.

Figure 5.

Cytotoxicity assay (MTT) for HT-29 colon cancer cells post-treatment with free Dox, and with non-targeted (NT) and CA IX targeted- (T), unloaded and Dox-loaded Au NPs, bearing either amide (AM) or hydrazone (HZN) groups, under normoxic and hypoxic conditions. Note that CA IX targeted, HZN-bearing Au nanoplatform THZN enhanced the toxicity of doxorubicin under hypoxic conditions as compared with the non-targeted nanoplatform NTHZN (P < 0.001) and it also reversed the hypoxia-induced chemoresistance, observed for the free doxorubicin